ALTME.PA stock +15.91% intraday on EURONEXT: momentum opens short-term targets
TME Pharma N.V. (ALTME.PA) on EURONEXT jumped 15.91% intraday to trade at EUR 0.0765, making it one of today’s top gainers in Europe. ALTME.PA stock rallied on heavy volume of 1,394,001 shares versus an average of 253,930, focusing trader attention on clinical collaborations and short-term technical breakouts. We review what moved the tape, the company’s fundamentals, and how market structure and forecasts shape near-term price targets.
Intraday move and key market data for ALTME.PA stock
ALTME.PA stock moved from an open of EUR 0.07 to a day high of EUR 0.08, with a previous close of EUR 0.07. The intraday volume of 1,394,001 is 5.49x the 50-day average, signalling active repositioning. The stock’s year range is EUR 0.05 – EUR 0.15, so today’s spike tests shorter-term resistance near the 50-day average of EUR 0.06.
Fundamentals and valuation context
TME Pharma N.V. (ALTME.PA) is a clinical-stage biotech in Healthcare on EURONEXT with market cap EUR 7,997,770.00 and 94,091,417 shares outstanding. Trailing EPS is -0.05 and PE reads -1.70, reflecting negative earnings. Price-to-sales is 173.86, and book value per share is negative; these metrics underline a high-risk biotech valuation with limited revenue traction.
Technical picture and trading signals for ALTME.PA stock
Technicals show momentum: RSI 51.52, Stochastic %K 91.43 and ADX 22.92, consistent with a fresh intraday uptrend. Bollinger Bands sit at 0.05 / 0.06 / 0.07, and the 50-day average is EUR 0.06 while the 200-day average is EUR 0.09. High relative volume and overbought stochastics suggest potential short-term continuation with quick profit-taking risk.
Meyka AI grade and model forecast
Meyka AI rates ALTME.PA with a score of 61.42/100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of EUR 0.06, a quarterly price of EUR 0.10, and a 12-month target of EUR 0.2578833364. Versus the current price (EUR 0.0765), the 12-month model implies an upside of 237.09%. Forecasts are model-based projections and not guarantees.
Clinical pipeline, partnerships and catalysts affecting ALTME.PA stock
TME Pharma’s lead candidate NOX-A12 is in combination trials and the company lists a collaboration with Merck to study NOX-A12 plus Keytruda in metastatic pancreatic cancer. Clinical readouts, trial enrollment updates, or partnership news typically drive outsized moves in small-cap biotech names like ALTME.PA. Any positive interim data would likely trigger more buying; setbacks would reverse gains quickly.
Risks, liquidity and sector comparison
ALTME.PA sits in Healthcare/Biotechnology where average PE is 34.18 for listed peers; ALTME’s negative earnings profile and limited cash per share (EUR 0.02) increase dilution and binary outcome risk. Liquidity improved intraday but average daily volume is low historically, so price gaps and volatility are likely. Investors should weigh sector performance and clinical binary risks before adding exposure.
Final Thoughts
Today’s intraday gain makes ALTME.PA stock a top gainer on EURONEXT, powered by 15.91% upside and unusually high volume of 1,394,001 shares. The move reflects short-term momentum and attention to TME Pharma N.V.’s clinical partnerships, but fundamentals remain early-stage: EPS -0.05, PE -1.70, and market cap EUR 7,997,770.00. Meyka AI’s forecast model projects a 12-month level near EUR 0.2578833364, implying +237.09% from the current price (EUR 0.0765); this scenario assumes successful clinical progress or broader investor re-rating. Conversely, negative trial news or dilution risk could erase gains rapidly. Our take: traders can use tight stops to capture intraday momentum, while longer-term investors should wait for clinical clarity or stronger financials. For real-time alerts and a full data feed on ALTME.PA stock see Meyka AI’s market page and the company site for filings.
FAQs
What drove ALTME.PA stock higher today?
ALTME.PA stock rose intraday on heavy volume, likely driven by renewed attention to its NOX-A12 clinical collaborations and short-term technical breakout above the 50-day average.
What is Meyka AI’s rating for ALTME.PA stock?
Meyka AI rates ALTME.PA 61.42/100 (Grade B) with a HOLD suggestion. The grade factors in benchmark and sector comparisons, key metrics, financial growth and analyst inputs.
What price targets exist for ALTME.PA stock?
Meyka AI’s model projects a quarterly target of EUR 0.10 and a 12-month model target of EUR 0.2578833364, implying +237.09% versus the current price of EUR 0.0765. Forecasts are not guarantees.
How risky is trading ALTME.PA stock?
ALTME.PA stock is high risk: negative earnings, tight cash per share, and clinical binary events dominate valuation. Intraday liquidity can spike, increasing volatility and gap risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
